2006 survey 2013 survey  
  Patients treated for HCV infection Patients NOT treated for HCV infection Total (%) Patients treated for HCV infection Patients NOT treated for HCV infection Total (%) P*
  Number % Number %   Number % Number %    
HCV RNA copies/ml
Positive 141 - 102 - 243 94 - 71 - 165 0.84
<800,000 64 - 53 - 117 37 - 30 - 67 1
>800,000 77 - 49 - 126 55 - 37 - 92 0.89
Negative 64 - 26 - 90 104 - 48 - 152 0.77
Not done/missing 17 - 33 - 40 12 - 11 - 23 0.2
HCV genotype
Genotype 1 105 49 66 50 171 (50) 116 60 44 56  160 (59) 0.036
Genotype 2 22 10 7 5 29 (8) 6 3 1 1  7 (3) 1
Genotype 3 61 29 32 24 93 (27) 35 18 19 24  54 (20) 1
Genotype 4 25 12 27 20 52 (15) 34 18 15 19  49 (17) 0.043
Genotype 5 0 0 0 0 0 (0) 1 1 0 0  1 (1) .
Genotype 6 0 0 0 0 0 (0) 0 0 0 0 0 .
Liver damage assessment
Liver biopsy and/or non invasive markers 213 100 112 100 325 (78) 175 100 78 100  253 (74) 0.37
Liver biopsy only 106 47 41 25 147 (35) 14 8 4 5  18 (5) 0.78
Non invasive markers only 40 18 53 32 93 (22) 87 50 57 73  144 (42) 0.011
Both 67 30 18 11 85 (20) 73 42 16 21  89 (26) 0.7
None 14 6 52 32 66 (16) 21 12 30 38  51 (15) 0.025
Table 2: Main characteristics of HCV infection in HIV-HCV co-infected patients, in those who had received HCV treatment and those who had never been treated in the 2006 and 2013 surveys.*P corresponds to the comparison between 2006 and 2013 surveys.
Goto home»